Blurbs

Wedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aquestive Therapeutics (AQSTResearch Report) today and set a price target of $4.00. The company’s shares closed today at $1.44.

Moussatos covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Aquestive Therapeutics, and Verona Pharma. According to TipRanks, Moussatos has an average return of -7.4% and a 33.23% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aquestive Therapeutics with a $5.67 average price target, representing a 293.75% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

AQST market cap is currently $81.09M and has a P/E ratio of -0.86.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Read More on AQST:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos